Tumor Comprehensive Genomic Profiling Panel Assay-Xiamen Spacegen Co., Ltd. | Precision Medical Testing & Genetic Disease Diagnosis Solutions

High-Throughput Sequencing

Tumor Comprehensive Genomic Profiling Panel Assay

1200 hot genes of solid tumors, including MSI, TMB, HRR, HLA, immune resistance, hyperprogression and other biomarkers.Provides information for clinically actionable genomic alterations and their associated targeted therapy, both approved and in clinical trials ; TMB / MSI / immunotherapy super progression, positive and negative factors to better inform immunotherapy decisions ; Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers； Reveals potential resistance mechanism(s) to current therapies and options for alternative treatments；Indicate some genetic risks by the detection of hereditary cancer-related genes.

BACKGROUND

Tumor initiation and progression are governed by complex mechanisms. While many tumor-associated genes have been discovered, the functions of numerous genes remain to be explored. Large-scale genomic testing comprehensively characterizes tumor genomic profiles and detects rare mutations in key genes. NGS large-panel sequencing guides individualized therapy, helps improve overall survival and offers more therapeutic options and clinical benefits for patients with advanced tumors.

DETECTED TARGETS

Covers 1,200 hotspot genes for solid tumors, including biomarkers such as MSI, TMB, HRR, HLA, immunotherapy resistance and hyperprogression, to comprehensively meet clinical testing requirements.

1、162——Targeted therapy-related genes

2、147 ——Hereditary tumor-related genes

3、164 ——MSI loci

4、65 ——Immunotherapy-related genes

5、473——Signaling pathway-related geness

6、53——Chemotherapy drug-related loci

7、TMB——Tumor Mutational Burden (TMB)

PRODUCT INFORMATION

Project Name

Assay Method

Packing Specification

Compatible Platforms

Specimen Material

Tumor Comprehensive Genomic Profiling panel Assay

NGS

24 Tests/ Kit

Platform-agnostic, compatible with Illumina, MGI and more sequencers

Somatic: Tumor tissue samples, cell-free DNA, pleural & ascitic fluid ; Germline: Peripheral blood

APPLICABLE POPULATION

1.Newly diagnosed solid tumor patients: Pre-treatment testing supports treatment planning and prognosis evaluation before targeted, immune or chemotherapy.

2.Solid tumor patients with targeted drug resistance or chemotherapy failure: genomic testing reveals resistance mechanisms and discovers new actionable variants.

3.Persons with family history of tumors needing hereditary cancer risk evaluation.

4.Solid tumor patients with above clinical requirements when pathological tissue is unavailable.

DETECTION SIGNIFICANCE

Targeted Therapy: Provides comprehensive tumor variant profiles including oncogenic pathway genes and rare loci. It interprets tumor pathogenesis, uncovers resistance mechanisms and guides rational targeted drug administration.

Immunotherapy: Comprehensively assesses immunotherapy outcomes based on TMB, MSI status, HLA typing, neoantigen prediction, and genes linked to treatment response and hyperprogression.

Chemotherapy: 53 chemotherapy-associated genes to evaluate efficacy and toxicities and refine chemotherapy strategies.

Hereditary Risk: 147 hereditary cancer genes to evaluate risks of hereditary tumors.

FEATURES & ADVANTAGES